Melanoma (Skin)
359
20
31
232
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Published Results
44 trials with published results (12%)
Research Maturity
232 completed trials (65% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
9.2%
33 terminated out of 359 trials
87.5%
+1.0% vs benchmark
8%
27 trials in Phase 3/4
19%
44 of 232 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 232 completed trials
Clinical Trials (359)
Rural Adult and Youth Sun Protection Study
Zr89 + PET Companion Trial
Nivolumab in Treating Patients With Stage IIB-IIC Melanoma That Can Be Removed by Surgery
Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases
MoleGazer Development Feasibility Study
Dermoscopy Augmented Histology Trial, Consensus Agreement Diagnosis Made by Dermatopathology Experts
High-Intensity Exercise and High-Fiber Diet for Immunotherapy Outcomes in Melanoma Patients: The DUO Trial
New Tumor Models in Three Dimensions and in a Human Skin Environment for Personalized Melanoma Therapy
A Study to Test the Benefit of Vitamin B5 in Patients With Melanoma
Cryotherapy With in Situ Immunotherapy in Melanoma Metastasis
Fianlimab&Cemiplimab as TotalNeoadj The (TNT) ForMelanoma
Identification of Metabolic Phenotypes Associated With Melanoma Metastasis
Phase I/IIa Study of 68GaNOTA-Anti-MMR-VHH2 for PET/CT
START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer
Effectiveness of Group and Individual Training in EFT for Patients in Remission From Melanoma
Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma
AI-based Medical Device Validation for Early Melanoma Detection
Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma